Trial Type: Melanoma and Skin Cancers

LS-P-IGNYTE-3
A Randomized, Controlled, Multicenter Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti‑PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Status: Open
Trial Type: Melanoma and Skin Cancers
Contact: Maria Constantinou, MD
mconstantinou@brownhealth.org
LS-P-DAnCE
A Phase 3 Study Of Fixed Dose Combinations Of Fianlimab And Cemiplimab Versus Nivolumab And Relatlimab In Participants With Unresectable Or Metastatic Melanoma
Status: Open
Trial Type: Melanoma and Skin Cancers
Contact: Maria Constantinou, MD
mconstantinou@brownhealth.org
CoAT
A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Status: Open
Trial Type: Melanoma and Skin Cancers
Contact: Aryeh Pelcovits, MD
ari.pelcovits@brownhealth.org
HAT
A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
Status: Open
Trial Type: Esophageal Cancer, Gastric Cancer, Melanoma and Skin Cancers, Ovarian Cancer, Soft Tissue and Bone Cancer
Contact: Benedito Carneiro, MD
Benedito.carneiro@brownhealth.org
BrUOG 416
Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis
Status: Open
Trial Type: Melanoma and Skin Cancers
Contact: Maria Constantinou, MD
mconstantinou@brownhealth.org
HEAT Trial
Bifunctional antibody against EGFR and TGF Beta, alone and in combination with pembrolizumab for Head and neck cancer, NSCLC and anal cancer and cutaneous squamous cell cancer
Status: Open
Trial Type: Early Phase Trials for Multiple Cancer Types, Head and Neck Cancer, Lung Cancer, Melanoma and Skin Cancers
Contact: Ariel Birnbaum, MD
abirnbaum@brownhealth.org

©2025 Brown Cancer Trials